Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 1/20 | 0.33 |
| ▸ | IGF1R | P08069 | 1/20 | 0.32 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.32 |
| ▸ | PRKDC | P78527 | 1/20 | 0.32 |
| ▸ | CDK4 | P11802 | 1/20 | 0.31 |
| ▸ | CCND1 | P24385 | 1/20 | 0.31 |
| ▸ | CCND2 | P30279 | 1/20 | 0.31 |
| ▸ | CCND3 | P30281 | 1/20 | 0.31 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.30 |
| ▸ | LYN | P07948 | 1/20 | 0.30 |
| ▸ | SRC | P12931 | 1/20 | 0.30 |
| ▸ | BTK | Q06187 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2984535 | 0.93 | — | — | |
| SCHEMBL2983650 | 0.93 | SRC (0.34) | IGF1RFGFR1CDK4CCND1CCND2 | |
| SCHEMBL2987877 | 0.91 | PDE3B (0.31) | — | |
| SCHEMBL2980347 | 0.89 | PDE3B (0.36) | PLK1IGF1RALDH1A1 | |
| SCHEMBL2974581 | 0.89 | — | — | |
| SCHEMBL2984529 | 0.88 | ADRB3 (0.30) | — | |
| SCHEMBL2973307 | 0.88 | PDE3B (0.41) | FGFR1CACNA2D1TBK1 | |
| SCHEMBL2980471 | 0.88 | PDE3B (0.40) | FGFR1CACNA2D1TBK1 | |
| SCHEMBL2983864 | 0.87 | PDE3B (0.36) | FGFR1PRKDCCACNA2D1KDM4EALDH1A1 | |
| SCHEMBL2980391 | 0.87 | PDE3B (0.42) | FGFR1CACNA2D1TBK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1831207-B1 | AMINOPYRIMIDINE COMPOUNDS AS PLK INHIBITORS | AMGEN INC (US) | 2012-11-14 | — | — | EP | claimed |
| US-7786132-B2 | Aminopyrimidine compounds and methods of use | AMGEN INC. (US) | 2010-08-31 | — | — | US | claimed |
| EP-1831207-A1 | AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE | Amgen Inc. (US) | 2007-09-12 | — | — | EP | claimed |
| US-20070185133-A1 | Aminopyrimidine compounds and methods of use | AMGEN, INC. (US) | 2007-08-09 | — | — | US | claimed |
| WO-2006066172-A1 | AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE | AMGEN, INC. (US) | 2006-06-22 | — | — | WO | claimed |
| EP-1831207-B1 | AMINOPYRIMIDINE COMPOUNDS AS PLK INHIBITORS | AMGEN INC (US) | 2012-11-14 | — | — | EP | disclosed |
| US-7858785-B2 | Aminopyrimidine compounds and methods of use | AMGEN INC. (US) | 2010-12-28 | — | — | US | disclosed |
| US-7786132-B2 | Aminopyrimidine compounds and methods of use | AMGEN INC. (US) | 2010-08-31 | — | — | US | disclosed |
| US-20100010014-A1 | AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2010-01-14 | — | — | US | disclosed |
| EP-1831207-A1 | AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE | Amgen Inc. (US) | 2007-09-12 | — | — | EP | disclosed |
| US-20070185133-A1 | Aminopyrimidine compounds and methods of use | AMGEN, INC. (US) | 2007-08-09 | — | — | US | disclosed |
| WO-2006066172-A1 | AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE | AMGEN, INC. (US) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100010014-A1 | AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE | PLK1, TYMP, TK2 | PLK1 1/4885IGF1R 3237/4885FGFR1 1230/4885 |
| US-20070185133-A1 | Aminopyrimidine compounds and methods of use | PLK1, TYMP, TK2 | PLK1 1/4885IGF1R 3237/4885FGFR1 1230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.